seudomonal antibiotics, thus accelerating appearance of resistance. Repression of the AmpC b -lactamase is controlled within the organism itself. Mutants produce excessive amounts of the AmpC b -lactamase when exposed to some antibiotics. Third-generation cephalosporins and ticarcillin-clavulanate select for these "derepressed" mutants. Extended-spectrum b -lactamases (ESBLs) hydrolyze third-generation cephalosporins, in addition to antipseudomonal penicillins and the fi rst-and second-generation cephalosporins ( Table 1 ). The genetic mechanisms for acquisition of ESBLs are related to insertion sequences, transposons , and integrons. 17 Carbapenems are the drugs of choice for P aeruginosa that produce ESBLs, because carbapenems are not inactivated by most ESBLs. Transferable b -lactamases, including the metalloenzymes, require zinc ions for activity (also called class B b -lactamases). They are not affected by b -lactamase inhibitors, such as clavulanate and sulbactam. They can also hydrolyze cephalosporins and carbapenems. 18 With the appearance of these metalloenzymes, the proportion of P aeruginosa that is resistant to carbapenems is increasing; VIM-2 is the dominant carbapenemase in P aeruginosa . 19 Some endogenous cephalosporinases of P aeruginosa may also confer resistance to imipenem. 20 The abbreviations of these b -lactamases are not in any standard or logical format, rendering nomenclature interpretable only to researchers in the fi eld.
Effl ux pump mechanisms actually remove the antibiotic before it can attach to its target site ( Table 2 ) . 16 The most relevant pump is Mex AB-OprM, which conveys resistance to quinolones, antipseudomonal penicillins, and third-generation cephalosporins. 21 Aminoglycoside resistance in P aeruginosa is often due to aminoglycoside-modifying enzymes, the most common of which is acetyltransferase. 22 Enzymatic modifi cation of the aminoglycoside structure results in decreased ability of the aminoglycoside to bind to the ribosome of the P aeruginosa . Amikacin is the least vulnerable to such mechanisms, because multiple enzymes are necessary for inactivation. Reduced uptake of the aminoglycoside mediates resistance to all aminoglycosides, including amikacin. Novel aminoglycoside resistance gene cassettes are being elucidated-in the worst case scenario, these are being discovered within integrons that also encode metalloenzymes. 23 Bacterial DNA gyrases maintain the bacterial chromosome in a supercoiled state and repair breaks in DNA that occur during replication. The quinolones act by inhibiting the activity of DNA gyrase enzymes; this leads to interference with DNA replication and cell death. Quinolone resistance is attributable to mutations in the DNA gyrases. The relative in vitro similar to the antipseudomonal cephalosporins, but it has not been a favored choice mainly because of relative lack of activity against gram-positive bacteria and anaerobes, organisms that are often isolated with P aeruginosa . The two quinolones considered as antipseudomonal agents are ciprofl oxacin and levofl oxacin ( Table 1 ) . Although ciprofl oxacin has a lower minimal inhibitory concentration (MIC) (0.5 m g/mL) compared with levofl oxacin (1.0 m g/mL) against P aeruginosa , the superiority of the slightly lower MIC of ciprofl oxacin is offset by its lower serum and tissue concentrations as compared with levofl oxacin, resulting in similar potency of these two antibiotics against P aeruginosa .
Epidemiology of Resistance
Emergence of antimicrobial resistance in P aeruginosa is growing ( Table 2 ) . [1] [2] [3] [4] [5] [6] [7] [8] Three large-scale US surveillance databases [5] [6] [7] have demonstrated increasing resistance rates for P aeruginosa for fl uoroquinolones (from 15% to 40%), third-generation cephalosporins (from 15% to 32%), and carbapenems (from 13% to 23%) in the past 9 to 13 years. P aeruginosa isolated from the respiratory tract contributed 57% to 67% of the isolates. 5, 6 Intubated patients in the ICU can acquire multidrug-resistant (MDR) P aeruginosa within 10 days after initiation of antipseudomonal antibiotics. 9, 10 Cross-resistance is common. For example, piperacillinresistant and ciprofl oxacin-resistant P aeruginosa exhibited higher prevalence of resistance to other antibiotic classes compared with piperacillinsusceptible and ciprofl oxacin-susceptible P aeruginosa , respectively 11, 12 Antimicrobial Resistance P aeruginosa has emerged as the epitome of MDR gram-negative bacilli causing hospital-acquired pneumonia (HAP). [13] [14] [15] It possesses at least five distinct mechanisms for inducing antibiotic resistance (innate resistance). Moreover, it has the capability of acquiring genes encoding antibiotic resistance (acquired resistance). Three mechanisms of resistance predominate: production of b -lactamases, loss of outer membrane proteins, and upregulation of efflux pumps ( Table 2 ) . Mutational gyrases and inactivating enzymes are specifi c for quinolones and aminoglycosides, respectively. These mechanisms can be present simultaneously, thereby conferring MDR. 16 Numerous b -lactamases are elaborated by P aeruginosa leading to widespread and unpredictable resistance patterns. The AmpC gene produces a b -lactamase that is the most common b -lactamase found in P aeruginosa . This b -lactamase has the characteristic of being "inducible" by various antip-including colistin. Acquisition of resistance in pathogenic bacteria usually leads to decreased virulence (the fi tness hypothesis). However, laboratory studies of MDR P aeruginosa have shown evidence for both decreased virulence [29] [30] [31] and maintenance of virulence. 32 
PK/PD Considerations
Aminoglycosides are concentration-dependent antibiotics. Such antibiotics effectively eradicate the target bacteria when concentrations are Ն 10 times above their MIC. In animal models of infection, animals are more likely to survive a potentially lethal challenge of bacteria if the aminoglycoside is given as a single daily dose rather than when given in divided doses every 8 h. In contrast, b -lactam agents are classifi ed as time-dependent antibiotics; for these agents, constant infusion maximizes the pharmacodynamic concept of time above the MIC. Pharmacy preparation costs are decreased for once-daily dosing and constant infusion administration. 33, 34 At least seven studies have compared the clinical effi cacy of continuous and intermittent b -lactam administration ( Table 3 ) . [34] [35] [36] [37] [38] [39] [40] In fi ve studies, patients with P aeruginosa pneumonia were included, ranging from 13% (4/31) to 53.1% (103/194) of the study population. 34, 36, 37, 39, 40 These fi ve studies used piperacillin/tazobactam, imipenem/cilastatin, meropenem, and ceftazidime for treatment. Clinical efficacy was assessed by mortality and treatment outcome (cure, improved, failure). Two studies demonstrated the superior effi cacy of continuous infusion, 36, 39 and the other three found no difference in the two infusion strategies. 34, 37, 40 The remaining two studies did not explicitly name the causative pathogen or infection site of the study population, but continuous infusion produced improved outcome. 35, 38 Constant infusion has been shown to be superior to intermittent administration in achieving pharmacodynamic targets. 41, 42 Thus, strong consideration should be given for the use of constant infusion of antipseudomonal b -lactam antibiotics for P aeruginosa pneumonia.
Merely slowing the rate of IV infusion from 1 to 4 h has also been applied for antipseudomonal antibiotics, particularly meropenem and doripenem. This increases the target time above the MIC during any one dosing interval, allowing for treatment of pathogens requiring higher MICs for their eradication. Doripenem is the most active carbapenem in vitro against P aeruginosa . 43, 44 In a prospective randomized trial of doripenem vs imipenem in 531 patients with ventilator-associated pneumonia (VAP), the clinical and microbiologic cure rate in patients with P aeruginosa pneumonia was higher in patients receiving doripenem compared with those receiving imipenem, although the results were not statistically signifi cant. 45 activity of antipseudomonal quinolones, ciprofl oxacin and levofl oxacin, is lower than that of b -lactam agents. 24 P aeruginosa requires greater time of exposure to quinolones 25 as compared with Streptococcus pneumoniae , which is rapidly killed by quinolones.
Outer membrane impermeability is a mechanism of resistance for several different classes of antibiotics ( Table 2 ). The most common mechanism by which P aeruginosa becomes carbapenem resistant is via mutational loss of outer membrane protein (OprD). Mutational loss of OprD is a frequent occurrence during imipenem therapy; imipenem resistance has emerged during treatment of P aeruginosa infections treated with the drug. 21, 26 Fortunately, loss of OprD does not confer resistance to b -lactams other than the carbapenems.
Resistance of P aeruginosa to colistin is rare and occurs most commonly in patients with cystic fi brosis who have received aerosolized colistin therapy. 27 Structural modifi cations of the outer membrane protein are responsible for high-level resistance of P aeruginosa to colistin. 28 Within the ICU, MDR P aeruginosa is often isolated from patients with pneumonia; these isolates are susceptible in vitro only to colistin. Pan-drug-resistant (PDR) P aeruginosa are resistant to all commercially available antibiotics, 47 Thus, colistin dosing every 6 to 8 h may be ideal.
Antibiotic Therapy
Initiation of appropriate empiric antibiotic treatment in a timely manner may decrease mortality in hospitalized patients with pneumonia. We reviewed 17 studies ( Table 4 ) [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] : 14 studies conducted in ICUs in patients with VAP, [48] [49] [50] [51] [52] [53] [55] [56] [57] [59] [60] [61] [62] 64 one study in patients with generalized infection, 58 and two studies in patients with bacteremia. 54, 63 In the latter three studies, pneumonia contributed to 16.0% to 62.7% of the study population. 54, 58, 63 The proportion of P aeruginosa as causative pathogen for pneumonia ranged from
The polymyxins also exhibit concentrationdependent antibacterial activity, with area under the concentration-vs-time curve as the best predictor of their activity in nonclinical models of infection. 41 A rapid bacterial kill in a concentration-dependent fashion was observed using time-kill methods with a substantial inoculum effect. Polymyxin exhibits an unusual phenomenon of a negative postantibiotic effect, which means that the growth of P aeruginosa markedly increases within 2 to 6 h once polymyxin concentrations drop below the MIC for P aeruginosa . 46 Heteroresistance may account for the rapid regrowth as susceptible strains are replaced by resistant subpopulations. Greatest suppression of resistance was seen for a tid dosing regimen of colistin in a pharma- nasal route in four studies 70, 72, 74, 75 or the intratracheal route in two studies. 71, 73, 74 The end points were mortality in fi ve studies. [70] [71] [72] [73] 75 In addition, clearance of P aeruginosa from lung was addressed in three studies. 71, 73, 74 Combination therapy led to signifi cantly lower mortality in two studies 71, 75 and a favorable trend in two other studies. 70, 73 Ceftazidime plus clarithromycin was superior to both ceftazidime monotherapy and clarithromycin monotherapy. 75 The combination of cefsulodin plus tobramycin led to lower mortality as compared with b -lactam agent monotherapy 71 but not to tobramycin monotherapy. The combination of ceftazidime plus tobramycin was superior to monotherapy of either drug in one study, but statistical signifi cance was not attained. 73 In the Rusnak et al 72 study, in vitro synergy was present for four combinations (ticarcillin plus tobramycin, ceftazidime plus tobramycin, azlocillin plus tobramycin, ceftazidime plus methicillin); however, none of these combinations signifi cantly improved mortality compared with the monotherapy regimens (azlocillin, ceftazidime, tobramycin, methicillin). Clearance of bacteria from lung tissue was also evaluated in three studies. 71, 73, 74 No signifi cant improvement was seen in one study using cefsulodin plus tobramycin. 71 Increased clearance was seen for ceftazidime plus tobramycin. 73 Increased clearance was seen for mezlocillin plus tobramycin in neutropenic animals but not in nonneutropenic animals.
Combination vs Monotherapy for P aeruginosa Pneumonia in Patients
Combination therapy can broaden the antimicrobial spectrum, provide synergistic interaction, decrease emergence of antimicrobial resistance, and minimize superinfection. However, demonstrated improvement in outcome for combination therapy has been elusive. Early studies that documented decreased mortality in patients receiving combination therapy used antibiotics that are no longer used in the current era. 77, 78 Moreover, most of the earlier studies involved neutropenic patients with bacteremia. With the advent of broad-spectrum and bactericidal antibiotics, such as third-or fourth-generation cephalosporins or carbapenems, it has been suggested that an additional aminoglycoside antibiotic might be unnecessary. 79 In a prospective study of P aeruginosa bacteremia, 80 combination therapy was assessed in vitro in 123 patients. Checkerboard assays and time-kill curve studies were performed using the antibiotics that the patients received. No improvement in mortality was seen for administration of synergistic combinations assessed by checkerboard methodology. However, improvements in mortality were seen for administration of synergistic combinations as defi ned by results 14.4% to 100% in these studies ( Table 4 ). Ten studies found that initiation of appropriate empirical antibiotic treatment in a timely manner signifi cantly decreased mortality in hospitalized patients with pneumonia, whereas seven studies did not.
In one study of P aeruginosa bacteremia 54 and two studies of VAP, 51, 57 the authors noted that the infection could be so severe that death was imminent despite initiation of appropriate empirical antimicrobial agent therapy. In the remaining studies, three attributed the insignifi cant results to the insuffi cient statistical power and one provided no explanation. 49, 52, 56, 60 Nevertheless, mortality was 3.6% to 40.2% in patients with appropriate empirical therapy and increased to 17.6% to 81.6% in those receiving inappropriate empirical antibiotic therapy. Furthermore, modifi cation of initial inappropriate treatment after a delay of 48 to 72 h failed to improve mortality. 36, 55, 61 Isolated pathogens resistant to the empirically prescribed antimicrobial agents were a common reason for initial treatment classifi ed as inappropriate, with contributions of 18% to 75.0%. 55, 58, 59, 62 P aeruginosa was the most common drug-resistant gram-negative bacterium. 55, 62, 64 
Combination Antibiotic Therapy vs Monotherapy
In Vitro Studies: For combination therapy, the greatest likelihood of synergy is an aminoglycoside with an antipseudomonal penicillin (~ 90%), and then, in decreasing order, with a cephalosporin (~ 80%) or a carbapenem (~ 50%). The interaction of fl uoroquinolones combined with b -lactams or aminoglycosides was usually autonomous (additive) or indifferent. 65, 66 For quinolone combinations plus antipseudomonal b -lactams, the b -lactam drug accomplished most of the bacterial killing. 65, 66 In a pharmacodynamic model, levofl oxacin combined with meropenem were synergistic (3-log cell kill) and had higher resistance suppression. 67 Monotherapy with any quinolone for the management of confi rmed P aeruginosa pneumonia is not recommended, given the high likelihood of the development of bacterial resistance (38%) and the failure to achieve bacteriologic eradication during therapy (67%). 68 This is not surprising owing to the low likelihood for either levofl oxacin or ciprofl oxacin to attain the target 24-h area under the concentrationvs-time curve ratio of . 100. 69 
Combination Antibiotics in Animal Models
Several animal studies have assessed the impact of combination therapy for P aeruginosa pneumonia. [70] [71] [72] [73] [74] [75] [76] Guinea pigs were used in four studies and mice in two studies. 70, 75 In two studies, neutropenia was induced by cyclophosphamide. 72, 74 Mucoid P aeruginosa was used in three of the studies. 70, 74, 75 Pneumonia was induced by inoculation of P aeruginosa via the intra-portion of patients receiving initial appropriate antibiotics was signifi cantly higher in those receiv ing combination therapy than in those receiving monotherapy 48, 93 ; microbiologic eradication of P aeruginosa was also signifi cantly higher. 93 In a prospective study of 28 ICUs in patients with VAP due to Pseudomonas and Acinetobacter species, no signifi cant differences were found for combination antibiotic therapy vs monotherapy. However, the appropriateness of antibiotic therapy as defi ned by in vitro susceptibility and microbiologic eradication was signifi cantly higher for those patients receiving combination therapy. 93 In a meta-analytic/meta-regression study of randomized and observational studies of serious bacterial infection, combination antibiotic therapy was found to improve outcome for those patients who were severely ill as defi ned by sepsis and septic shock. 94 This meta-analysis included studies of P aeruginosa bacteremia and two studies of P aeruginosa VAP.
In their Cochrane review, Paul et al 84 concluded that no clinical benefi t is accrued, whereas nephrotoxicity with an aminoglycoside was a disadvantage for combination therapy. We point out that duration of aminoglycoside use correlates with nephrotoxicity. Duration in the early studies of neutropenic patients was . 10 to 14 days. In a study of 21 patients with AIDS with P aeruginosa bacteremia, 95 the median duration was 12 days (maximum 32 days). (In this study, mortality was signifi cantly lower for those who received combination antibiotic therapy with an aminoglycoside.) In another study of 604 patients with febrile neutropenia, amikacin or tobramycin were given for 16.6 days (range 15.5-122 days). 96 Aminoglycoside toxicity would thus be minimal if duration was limited to 5 days or fewer. 97 Chamot et al 54 found that empirical combination therapy signifi cantly increased survival even if the aminoglycoside was given only for 3 to 5 days, followed by monotherapy.
The emergence of MDR makes monotherapy a tenuous strategy in severely ill patients with the likelihood of P aeruginosa pneumonia. Because initial appropriate antimicrobial treatment is critical to decreasing mortality rate in patients with pneumonia, prescription of combination therapy for patients with P aeruginosa pneumonia would increase the probability of therapy that is active in vitro. Toxicity of the aminoglycoside component can be mitigated by shortening the duration of aminoglycoside therapy or substituting a quinolone for the aminoglycoside. We would thus recommend combination therapy for patients suspected of having P aeruginosa pneumonia, especially in a hospital with endemic MDR P aeruginosa . Although randomized controlled trials are ideal, logistic considerations for such a study are almost insurmountable. The obstacles include the large number of patients required to attain statistical from time-kill curves: 46% (56/123) survived who received a synergistic combination as compared with 28% (34/123) who received a nonsynergistic (indifferent or autonomous) combination. Although a clearcut trend was observed, statistical signifi cance was not attained, (Fisher exact test, two-tailed, P 5 .10).
Several meta-analyses have concluded that combination therapy did not offer a survival benefi t in patients with febrile neutropenia, gram-negative bacteremia, and sepsis; it is important to note that these meta-analyses were not directed specifi cally at P aeruginosa . [81] [82] [83] [84] Somewhat surprisingly, prevention of antimicrobial resistance and superinfection also was not seen with combination therapy, 81, 85 although nephrotoxicity occurred in patients receiving combination therapy. 81 In one meta-analysis of fi ve studies in which P aeruginosa was specifi cally evaluated, mortality decreased signifi cantly in patients receiving combination therapy. 82 However, in four of the fi ve studies in this meta-analysis, a single aminoglycoside was used as monotherapy, which might be considered inadequate treatment of P aeruginosa bacteremia. 83, 86 Because few studies compared the effi cacy of monotherapy with that of combination therapy in patients with P aeruginosa pneumonia, 48 studies regarding comparison of the two treatment strategies for pneumonia were pooled for this discussion. In nine pneumonia studies, P aeruginosa was the causative pathogen in 6.0% to 100%; two of these studies showed signifi cantly improved survival by combination therapy. 80, 87 In addition, one review 88 combined and summarized the results of treatment of pneumonia from two other reviews. 79, 81 The fi rst review included six studies in patients with HAP and one study in patients with HAP or severe communityacquired pneumonia. 79 The second review comprised at least 1,200 patients with HAP. 81 Success rates were similar in studies with monotherapy and in those with combination therapy except for two studies 89, 90 in which monotherapy was signifi cantly better. A meta-analysis for 11 trials with 1,805 patients compared the effi cacy of monotherapy with that of combination therapy for suspected VAP. 91 A total of 85.1% of the study patients underwent mechanical ventilation and P aeruginosa was the causative pathogen in 13.8% of the patients. The rates of mortality and treatment failure for monotherapy were similar to those for combination therapy. In a prospective study of 84 patients in a trauma ICU with P aeruginosa VAP diagnosed by quantitative BAL, all patients received empiric monotherapy. 92 A total of 94.1% achieved microbiological resolution; however, 5.9% required combination antibiotic therapy consisting of cefepime and aminoglycoside to achieve resolution. 92 In two studies of VAP, combination therapy did not improve mortality. 48, 93 However, the pro-approaches described by Singh et al 110 and Torres. 111 It should be noted that as many as 50% to 70% of patients with pulmonary infi ltrates who are treated for ICU pneumonia do not actually have an infection but have other conditions, including ARDS, congestive heart failure, atelectasis, and so forth. Thus, establishing that the patient has a true respiratory infection is important, because increased mortality occurs if antibiotics are given indiscriminately to ICU patients who are not infected 110, 112, 113 or not severely ill. 94 Severity of illness should be assessed ( Fig 1 ) : The various Acute Physiology and Chronic Health Evaluation (APACHE) scores or the Pitt Bacteremia Score 109 are useful quantitative scores. If the patient is severely ill, then empirical therapy is a necessity. Factors consistently predisposing to multidrug resistance include evidence of prior colonization or infection by MDR P aeruginosa as well as receipt of prior antibiotics during the ICU stay. [114] [115] [116] An antipseudomonal b -lactam that is not a carbapenem is generally preferred ( Fig 1 , Table 1 ). Local susceptibility patterns should guide initial empiric antibiotic therapy. If an antipseudomonal b -lactam has already been administered within the past 30 days, selecting another antipseudomonal antibiotic of a different class is indicated. If an aminoglycoside is selected as the second component of the combination, the aminoglycoside component might be limited to 3 to 5 days if a clinical or a bacteriological response is seen.
The CPIS score is used as a screening tool to identify patients who can receive short-course monotherapy safely ( Fig 1 ) . Given that colonization is a distinct possibility in a stable patient, as discussed previously, the use of CPIS score will minimize the possibility of overtreatment of P aeruginosa found in an innocent bystander. At the end of 3 days, the patient should be clinically re-evaluated ( Fig 2 ) . Respiratory tract culture results should be available ( Fig 2 ) . For patients who were not critically ill at outset and received monotherapy, the antibiotic can be discontinued if the CPIS remains low following 3 days of monotherapy. 110 Vigilant monitoring for subsequent signs of infection is then indicated.
Colistin Therapy
Given the emergence of MDR P aeruginosa , colistin has been resurrected ( Fig 2 ) . Its effi cacy has been reported in several uncontrolled series of ICU pneumonia. [117] [118] [119] [120] [121] [122] [123] [124] In a case control study of VAP caused by MDR P aeruginosa or Acinetobacter , a favorable clinical response was seen in 75% of those treated with IV colistin vs 72% treated with imipenem. 125 As mentioned previously, PK/PD studies suggest that divided doses every 6 to 8 h may be preferred over every 12 h dosing.
In vitro and animal model studies show synergy between colistin plus rifampin and colistin plus carbapenems against P aeruginosa , 126,127 although clinical power and the diffi culty in establishing a defi nitive diagnosis of P aeruginosa pneumonia.
We recommend an antipseudomonal b -lactam as the primary antibiotic for presumed P aeruginosa pneumonia ( Table 1 ) (Keep in mind our caveats on colonization in non-severely ill patients as discussed in the "Diagnosis" section of our previously published article 98 in this two-part series.) Given the possibility of autonomous (additive) or even synergistic interaction in this era of MDR, we would add an aminoglycoside for 3 to 5 days. 99 Once culture of respiratory secretions has confi rmed the presence of P aeruginosa , treatment could be adjusted based on in vitro susceptibility and the aminoglycoside could be discontinued. Antibiotic therapy could also be simplifi ed if respiratory tract cultures failed to yield P aeruginosa .
Although no randomized studies have compared the effi cacy of a quinolone vs an aminoglycoside as the second component of combination therapy, many ICU physicians have elected to use quinolones in combination with an antipseudomonal b -lactam agent to avoid the nephrotoxicity of the aminoglycoside. In a retrospective study of bacteremias caused by gramnegative bacilli, including P aeruginosa , mortality was lower for non-critically ill patients who received combination therapy with b -lactam agents plus quinolones as compared with b -lactam monotherapy. 100 We do not recommend combinations of two b -lactam agents. Double b -lactam therapy has proven inferior to the b -lactam-aminoglycoside combination in animal models. 101 Emergence of resistance occurred in 40% (2/5) of patients with P aeruginosa infection treated with double b -lactams. 102 Rifampin has been shown to be synergistic in vitro with antipseudomonal penicillin and aminoglycosides against P aeruginosa 103, 104 and to improve survival in a neutropenic mouse model of Pseudomonas bacteremia. 104, 105 This combination has also been used as successful therapy in a limited number of patients with P aeruginosa infections refractory to standard combination therapy. 106 A prospective randomized trial of an antipseudomonal b -lactam plus an aminoglycoside with or without rifampin was conducted in 121 patients with P aeruginosa bacteremia. 107 Although bacteriologic cure was demonstrated signifi cantly more frequently in patients randomized to the rifampin-containing regimen, survival was not signifi cantly different. Fosomycin was used successfully in combination with a carbapenem for six out of eight patients with MDR P aeruginosa pneumoniae. 108 
Algorithm for ICU Pneumonia
An evidence-based algorithm for P aeruginosa pneumonia in the ICU is provided for the reader's consideration ( Figs 1, 2 ) . 109, 110 It is derived, in part, from the of antibiotic therapy: 8 days vs 15 days. 134 Forty-two patients were infected by P aeruginosa as defi ned by quantitative bronchoscopy cultures. 134 The recurrence rate was signifi cantly higher in those who received 8 days vs 15 days of antibiotic therapy (40.6% vs 25.4%), although length of ICU stay and mortality were similar. In contrast, emergence of MDR pathogens was signifi cantly higher in those who received 15 days of therapy, an important fi nding that has been overlooked by many. The risk of recurrence must therefore be balanced against the emergence of an MDR or PDR P aeruginosa within that same patient. Thus, we propose to use 8 days of therapy if the diagnosis of P aeruginosa is presumptive and clinical stability has been achieved within 3 days. On the other hand, if the P aeruginosa being treated is resistant to the empirical antibiotic initiated or if the ICU course has been complicated, then 15 days may be preferred ( Fig 2 ) . studies in humans have not supported the use of colistin-containing combinations. PDR P aeruginosa , resistant in vitro to all commercially available antibiotics, including colistin, has been implicated in VAP; the primary risk factor was combined use of colistin plus carbapenems for . 13 days. 128 Colistin has been reported to cause both reversible nephrotoxicity and reversible neurotoxicity [129] [130] [131] ; however, these adverse effects are diffi cult to discern in critically ill patients given the multiplicity of confounding factors. Colistin nephrotoxicity has been shown to be a manageable problem. 121, 122, 125, 132, 133 Interestingly, colistin is one of the few nephrotoxic drugs that has no ototoxicity.
Duration of Antibiotic Therapy
A prospective, randomized, double-blind trial in 51 ICU patients with VAP assessed optimal duration for recalcitrant pneumonia with MDR P aeruginosa in patients with cystic fi brosis. Aztreonam inhalation solution has been approved for patients with cystic fi brosis infected with P aeruginosa .
Conclusions
MDR P aeruginosa represents an emerging problem in ICUs owing to multiple bacterial resistance mechanisms. Based on assessment of in vitro studies, animal models, PK/PD data, and extensive clinical literature, we recommend an antipseudomonal b -lactam antibiotic in combination with an aminoglycoside or an antipseudomonal quinolone. The increasing resistance of P aeruginosa to quinolones may be a limiting factor. If possible, constant infusion of the b -lactam antibiotic should be used, for it provides more intense activity against this bacterium for a Aerosolized Antibiotics for P aeruginosa ICU Pneumonia: Aerosolized antibiotics consisting of aminoglycosides or colistin have been evaluated in patients with pneumonia with the underlying illnesses of cystic fi brosis or lung transplantation. Inhaled aminoglycosides lead to high drug concentrations in lung tissue, whereas serum concentrations are negligible. In patients with cystic fi brosis, inhaled tobramycin achieved 25 times the MIC for P aeruginosa in sputum, whereas serum concentrations were negligible. 135 Aerosolized colistin has been used successfully in anecdotal reports of pneumonia therapy and a retrospective case-control study, 136 usually as a supplement to IV therapy. [137] [138] [139] [140] [141] In a prospective randomized trial of aerosolized colistin in 100 patients with VAP, favorable outcome was essentially the same as control patients receiving aerosolized saline (about 50%). 142 With respect to combinations of aerosolized antibiotics, aerosolized colistin and tobramycin have been used (Table 1) ; †antipseudomonal carbapenems are imipenem, meropenem, doripenem; §add colistin as inhalation or parenteral therapy to the most active combination therapy; ‡local antibiotic susceptibility patterns within that institution should be considered; **duration of b-lactam therapy should be 8-15 days. The aminoglycoside/quinolone can be discontinued at 3-5 days based on results from in vitro susceptibility testing and clinical response. Note: The three antibiotic regimens displayed are intended for confi rmed P aeruginosa pneumonia in patients who have a CPIS . 6 and are critically ill. Deescalation is recommended if these conditions are not fulfi lled. See Figure 1 longer period of time and decreases labor costs (nursing and pharmacy time). Once-daily aminoglycoside dosing is superior pharmacodynamically and also more convenient. The duration of the aminoglycoside therapy should be limited to , 5 days if possible. Polymyxins (colistin) are used in some ICUs because these agents often remain the only antibiotics that exhibit activity against MDR P aeruginosa . A pragmatic algorithmic treatment approach of empirical antibiotic therapy for ICU pneumonia is presented.
